During the past decade, Dallas Diabetes & Endocrine Center conducted 27 clinical trials. In the 10-year time frame, 27 clinical trials started and 40 clinical trials were completed, i.e. on average, 148.1% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 15 clinical trials were completed. i.e. 375% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Dallas Diabetes & Endocrine Center" #1 sponsor was "Eli Lilly and Company" with 16 trials, followed by "Mannkind Corporation" with 8 trials sponsored, "AstraZeneca" with 4 trials sponsored, "Boehringer Ingelheim" with 4 trials sponsored and "Intarcia Therapeutics" with 4 trials sponsored. Other sponsors include 21 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Dallas Diabetes & Endocrine Center" #1 collaborator was "Astra Zeneca, Bristol-Myers Squibb" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Baylor Health Care System" with 1 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator and "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Dallas Diabetes & Endocrine Center" are "Type 2 Diabetes Mellitus" (15 trials), "Diabetes Mellitus, Type 2" (14 trials), "Type 2 Diabetes" (9 trials), "Type 1 Diabetes Mellitus" (4 trials) and "Cardiovascular Disease" (2 trials). Many other conditions were trialed in "Dallas Diabetes & Endocrine Center" in a lesser frequency.

Most popular intervention types in "Dallas Diabetes & Endocrine Center" are "Drug" (58 trials), "Other" (2 trials), "Behavioral" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (21 trials), "Metformin" (8 trials), "Insulin Glargine" (5 trials), "Dapagliflozin" (4 trials) and "Dulaglutide" (4 trials). Other intervention names were less common.

The vast majority of trials in "Dallas Diabetes & Endocrine Center" are 61 trials for "All" genders.

Currently, there are NaN active trials in "Dallas Diabetes & Endocrine Center". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 49 completed trials in Dallas Diabetes & Endocrine Center, undefined suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in Dallas Diabetes & Endocrine Center, 4 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 32 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".